Comparative Pharmacology
Head-to-head clinical analysis: LABETALOL versus PROCAINE HYDROCHLORIDE W EPINEPHRINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LABETALOL versus PROCAINE HYDROCHLORIDE W EPINEPHRINE.
Labetalol vs PROCAINE HYDROCHLORIDE W/ EPINEPHRINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Labetalol is a racemic mixture of four stereoisomers, each with distinct activity. It is a non-selective beta-adrenergic antagonist (blocking beta1 and beta2 receptors) and a selective alpha1-adrenergic antagonist. The alpha1 blockade causes vasodilation and reduces peripheral vascular resistance, while beta blockade reduces heart rate and myocardial contractility, leading to decreased blood pressure without significant reflex tachycardia.
Procaine is a local anesthetic that blocks voltage-gated sodium channels, preventing nerve impulse conduction. Epinephrine causes vasoconstriction via alpha-1 adrenergic receptor agonism, reducing absorption of procaine and prolonging its effect.
Oral: 200-1200 mg/day in 2 divided doses; initial 100 mg twice daily. IV: 20 mg bolus over 2 minutes, may repeat 40 mg at 10-minute intervals. Max cumulative dose: 300 mg.
2% procaine hydrochloride with epinephrine 1:200,000: Local infiltration or nerve block: up to 25 mL (500 mg procaine) as a single dose; maximum total dose 1000 mg per procedure. For epidural or spinal anesthesia: 5-20 mL (100-400 mg) as needed.
None Documented
Clinical Note
moderateLabetalol + Digitoxin
"Labetalol may increase the bradycardic activities of Digitoxin."
Clinical Note
moderateLabetalol + Deslanoside
"Labetalol may increase the bradycardic activities of Deslanoside."
Clinical Note
moderateLabetalol + Acetyldigitoxin
"Labetalol may increase the bradycardic activities of Acetyldigitoxin."
Clinical Note
moderateLabetalol + Ouabain
"Labetalol may increase the bradycardic activities of Ouabain."
None Documented
6-8 hours (terminal elimination half-life); may be prolonged in hepatic impairment, unchanged in renal impairment.
Procaine: 40–84 seconds (plasma), due to rapid hydrolysis. The terminal elimination half-life of procaine is approximately 7–8 minutes after hydrolysis, but the clinical effect is terminated by redistribution and metabolism. Epinephrine: 2–3 minutes.
Renal (55-60% as unchanged drug and metabolites); biliary/fecal (minor, approximately 5-10%); remainder metabolized in liver.
Renal excretion of procaine is minimal as it is rapidly hydrolyzed by plasma pseudocholinesterase to para-aminobenzoic acid (PABA) and diethylaminoethanol (DEAE). Less than 2% of unchanged procaine is excreted in urine. Metabolites are further processed and eliminated renally. Epinephrine is metabolized by catechol-O-methyltransferase and monoamine oxidase; metabolites are excreted in urine.
Category A/B
Category A/B
Alpha/Beta-Blocker
Alpha/Beta Agonist